DBV Technologies Reports Full Year 2017 Financial Results

DBV Technologies Reports Full Year 2017 Financial Results

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced full year 2017 results. Audit procedures on the Company's 2017 consolidated financial statements were completed by the Company's statutory auditors.

Cash Position: cash and cash equivalents as of December 31, 2017, were €137.9 million, compared to €256.5 million as of December 31, 2016, a decrease of €118.6 million.

Operating Income: operating income was €11.9 million in 2017 compared to €9.1 million in 2016, an increase of 31.1%. In 2017, income was primarily generated from the Company's Research Tax Credit (Crédit Impôt Recherche) and under the May 2016 collaboration agreement with Nestlé Health Science.

Research & Development Expenses: research and development expenses increased by €26.4 million, or 33.5%, to €105.2 million in 2017, compared to €78.8 million in 2016, reflecting increased costs associated with the Phase III and Phase II clinical trials of Viaskin Peanut and Viaskin Milk, respectively, as well as a substantial increase in the number of research and development personnel employed by the Company.

Sales & Marketing Expenses: sales and marketing expenses were €15.8 million for 2017 compared to €11.3 million for 2016, reflecting an increase of €4.5 million, or 40.3%. The increase in sales and marketing expenses resulted from an increase in U.S. employee headcount and expenses related to the potential launch and commercialization of Viaskin Peanut in North America, as well as an increase in share-based compensation.

General & Administrative Expenses: general and administrative expenses were €35.8 million for 2017, compared to €35.0 million for 2016. The increase in general and administrative expenses was primarily attributable to an increase in personnel-related expenses as a result of our increased global employee headcount and increased costs associated with legal and professional services, partially offset by decreases in share-based compensation and insurance expenses. 

Net Loss: net loss was €147.7 million for 2017, compared to €114.5 million in 2016. Loss per share (based on the weighted average number of shares outstanding over the period) was €(5.97) and €(4.68) in 2017 and 2016, respectively.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com   

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
[email protected]

DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
[email protected]

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/37a756a4-b894-4529-a691-1d89c65d15f7